Articles Tagged ‘suppression’

14
Jul
2010

Exploiting Mechanisms of Response and Resistance to Next Generation Androgen Pathway Antagonists Co-Leaders: Elahe Mostaghel, M.D., Ph.D., Stephen Plymate, M.D. The efficacy of agents targeting the androgen receptor (AR) axis in men with castration-resistant prostate cancer (CRPC) may differ markedly based on tumor-specific differences in the induction of AR pathway components. A

21
Jan
2010

Goutham Narla, M.D., Ph.D., Assistant Professor, Departments of Genetics & Medicine; Director, Physician Scientist Training, Residency Program, Mount Sinai School of Medicine